Perrigo Company plc - Form 8-K Summary
Business Context and Reporting Period
Perrigo Company plc (PRGO), incorporated in Ireland, filed this Current Report on August 5, 2026. The filing announces the release of earnings for the second quarter ended June 27, 2026. The company operates in the pharmaceutical sector and maintains a "Core" business definition that excludes infant formula currently under strategic review and previously announced divestitures.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It serves as a notification of the earnings release (Exhibit 99.1) rather than a detailed financial statement. The company reports both GAAP and non-GAAP measures, including adjusted gross profit, adjusted net income, and adjusted diluted earnings per share. Non-GAAP adjustments exclude amortization, unusual litigation, restructuring charges, impairment charges, and divestiture impacts.
Material Changes and Adjustments
While specific comparative figures are absent from this text, the company outlines the following adjustments made to derive non-GAAP results for the three months ended June 27, 2026, compared to the prior year period:
- Amortization expense related to acquired intangible assets.
- Unusual litigation costs.
- Restructuring charges and termination benefits.
- Impairment charges.
- (Gain) Loss on divestitures.
- Foreign currency translation movements.
- Items related to the Infant Formula business segment.
Guidance, Outlook, and Risks
Management utilizes non-GAAP measures for planning, forecasting, and compensation determinations. However, the company explicitly states it cannot reconcile its "All In" or "Core" expected organic net sales growth, margins, or earnings per share to GAAP measures without unreasonable effort. This limitation is due to uncertainties regarding non-recurring infant formula charges, the timing and amount of restructuring charges, and associated income tax effects. The filing highlights the strategic review of the infant formula business as a key contingency affecting financial predictability.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 revenue, earnings, and margin figures.
- Verify the reconciliation between GAAP and non-GAAP financial measures in the full earnings release.
- Assess the status and potential financial impact of the strategic review of the infant formula business.
- Monitor updates on restructuring charges and litigation costs excluded from non-GAAP results.
- Confirm the company's ability to provide forward-looking guidance given the stated reconciliation limitations.